ライフサイエンスコーパス: Gd

1 Gd-DOTA-PE nanoparticles had an ionic r1 of 13.3 L . mmo

2 Gd-ESMA enables targeting of elastin within the infarct

3 Gd-PyMTA turned out to be cell compatible and was proven

4 Gd-TREN-MAM is highly selective for phosphate over other

5 Gd@C-dots possess strong fluorescence and can effectivel

6 Gd@C82(OH)22 blocks epithelial-to-mesenchymal transition

7 (36)Cl and the alpha-emitters (154)Dy, (148)Gd, (150)Gd, and (146)Sm from Ta targets irradiated with

8 ons showed a satisfactory agreement for (148)Gd (less than within a factor two), while measured (154)

9 re analyzed concerning their content of (148)Gd, (173)Lu, and (146)Pm by use of alpha- and gamma-spec

10 The amount of (148)Gd, (173)Lu, and (146)Pm was then quantified by summing

11 work presents the determination of the (148)Gd and (154)Dy content in Pb targets irradiated by 220-2

12 nd the alpha-emitters (154)Dy, (148)Gd, (150)Gd, and (146)Sm from Ta targets irradiated with protons

13 cal relapses over 140 patient-years with 188 Gd-enhancing lesions on 48 pre-aHSCT MRI scans.

14 characterizable complexes of Tb(2+), Pr(2+), Gd(2+), and Lu(2+) have been isolated, which demonstrate

15 Toward MMP-2, Gd@C82(OH)22 could block either the Zn(2+)-catalylitic s

16 (MRI) contrast agent, CREKA-Tris(Gd-DOTA)3 (Gd-DOTA (4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyc

17 metal ions (RE(3+) = Y(3+), Sm(3+), Eu(3+), Gd(3+), Tb(3+), Dy(3+), Ho(3+), Er(3+), Tm(3+), Yb(3+))

18 e earth (RE) cations Pr(3+), Nd(3+), Sm(3+), Gd(3+), Er(3+) and Yb(3+) in anatase TiO2 have been synt

19 of single CNT bundles that encapsulate C 60, Gd@C 82 and Er 2@C 82.

20 nganese(II) complex [Mn(PyC3A)(H2O)](-) as a Gd alternative.

21 lished, which was efficiently catalyzed by a Gd-N,N'-dioxide complex.

22 To address a perceived need for a Gd-free contrast agent with pharmacokinetic and imaging

23 e healthy mouse prostate after infusion of a Gd-based Zn(II) sensor and an i.p. bolus of glucose.

24 signaling but rather Ca(2+) entry through a Gd(3+)-sensitive channel.

25 -ESMA) were compared with gadopentetic acid (Gd-DTPA) for infarct size determination, contrast-to-noi

26 ybenzyl-diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA) with dynamic contrast-enhanced MR imaging (

27 xcised outside-out patches, Ag NPs activated Gd(3+) -sensitive Ca(2+) influx channels with unitary co

28 In addition, Gd deposition in the human brain has been reported follo

29 peak above the Fermi level is observed after Gd adatoms are trapped inside Fe corrals, while two peak

30 TE 5300/67 ms), T1 + Gd-DTPA (contrast agent Gd-DTPA at 0.2 mmol/kg).

31 bing extravasation of the MRI contrast agent Gd-DTPA was significantly increased in both the sonicate

32 II) complex of DO3A-N-alpha-aminopropionate, Gd(DOTAla), was used to generate a small library of puta

33 Extracellular La(3+) and Gd(3+) rapidly and reversibly blocked the induced Pro(2+

34 only used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found to be 4.8 +/- 0.88, 46 +/-

35 ed to quantum confinement of the corrals and Gd structures trapped inside, are supported by tight-bin

36 MATERIAL/73 patients underwent DCECT and Gd-EOB-DTPA-3T-MR.

37 gher diffusivity than sodium diatrizoate and Gd-DTPA.

38 ts showed good agreement between Gd-ESMA and Gd-DTPA and were confirmed by ex vivo triphenyltetrazoli

39 ic double perovskites (MnR)MnSbO6 for Eu and Gd.

40 firm a ferromagnetic coupling between Fe and Gd across a 3 monolayers Sc spacer or a Mn spacer thicke

41 rved between delayed enhancement imaging and Gd-DTPA between days 7 and 21 (1.8+/- versus 3.8; P=ns),

42 cosaminoglycan content for sodium iodide and Gd-DTPA only, diffusivity significantly increased for al

43 eases in diffusivities for sodium iodide and Gd-DTPA, with similar (but not significant) trends for s

44 rnally loaded with both (225)Ac(3+) ions and Gd(3+) ions show 2 distinct populations of (225)Ac(3+) i

45 Aqueous loading of both (225)Ac(3+) ions and Gd(3+) ions via bath sonication was used to construct (2

46 ) to >1 mg day(-1) (e.g., Zn, Sc, Y, Nb, and Gd) and >1 g day(-1) (e.g., for P, Fe, and S).

47 phase is stabilized in zero field by Nd and Gd impurities, similarly to the case of Ce0.95Nd0.05CoIn

48 h spectroscopically orthogonal nitroxide and Gd(III)-based labels.

49 an +/- standard deviation) with Mn-PyC3A and Gd-DTPA was 476 +/- 77 and 538 +/- 120, respectively (P

50 (Papio anubis; n = 4) by using Mn-PyC3A and Gd-DTPA.

51 lcium uniporter inhibitors Ruthenium Red and Gd(3+), as well as to the Arabidopsis protein MICU, a re

52 RExMnSb11 (0 < x < 0.6, RE = Pr, Nd, Sm, and Gd) were synthesized by Sn flux.

53 e inclusion of rare earth metals (Eu, Tb and Gd) to produce a luminescent material which has been stu

54 to the interdiffusion of Y from the YIG and Gd from the substrate, an addition magnetic layer is for

55 ared, coencapsulating doxorubicin (dox) and [Gd(HPDO3A)(H2O)], and injected in tumor-bearing rats bef

56 iezo2 small interfering RNA and antagonists (Gd(3+) and D-GsMTx4).

57 order of magnitude increase in anthropogenic Gd concentrations in SFB, from 8.27 to 112 pmol kg(-1) o

58 in San Francisco Bay and that anthropogenic Gd concentrations increased substantially over a 20 year

59 uggest that the spin labeled peptide H-AP10C(Gd-PyMTA)P10C(Gd-PyMTA)P10-NH2 is inserted into cell mem

60 The resulting peptide, H-AP10C(Gd-PyMTA)P10C(Gd-PyMTA)P10-NH2, as well as the model com

61 g two contrast agents: a clinically approved Gd chelate, Multihance((R)) (gadobenate dimeglumine), an

62 ch mediates uptake of a clinically approved, Gd(3+)-based, hepatotrophic contrast agent (gadolinium-e

63 thrombus enhancement to the state of the art Gd analogue, EP-2104R, in a rat model of arterial thromb

64 entary strategies for developing new MnPs as Gd-free CAs with optimized biocompatibility were establi

65 ent or diminished in other f(7) ions such as Gd(III) or Cm(III).

66 used in new high-tech applications, such as Gd, are emerging contaminants in San Francisco Bay and t

67 ng (RIXS) experiments on Gd x Sc3-x N@C80 at Gd N 4,5-edges to directly study the electronic structur

68 tudy, all HCA subtypes were hypoenhancing at Gd-EOB-DTPA-enhanced MR imaging in the hepatobiliary pha

69 e measurements showed good agreement between Gd-ESMA and Gd-DTPA and were confirmed by ex vivo triphe

70 window for HCC chemotherapy, as monitored by Gd-DTPA-enhanced MRI as a noninvasive, clinically applic

71 mpounds are built from layers of Fe-centered Gd prisms stacked along c and surrounded by an Fe-C netw

72 ermined for the three commonly used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found t

73 Current clinical Gd(3+)-based T1 magnetic resonance imaging (MRI) contras

74 We also report that this amino-coated Gd-nanoplatform, when subsequently conjugated with inter

75 in blood plasma is comparable to commercial Gd contrast agents.

76 PyMTA)P10-NH2, as well as the model compound Gd-spacer-Gd, which consists of a spacer of well-known s

77 d T1 contrast in MR imaging by concentrating Gd(III) within the nanoparticle.

78 ligand, even under strong acidic conditions, Gd-TREN-MAM can be used at least 10 times in a pH-based

79 In normoxic conditions, Gd@C82(OH)22 mediates these effects by blocking TGF-beta

80 4.7 T, substantially surpassing conventional Gd(III) chelating agents (r1 approximately 3 mM(-1)s(-1)

81 y fabricated by calcination of corresponding Gd-organic precursor obtained via a facile hydrothermal

82 oFeP) from Gluconacetobacter diazotrophicus (Gd), which natively possesses an Ala residue in the posi

83 ate (Mn-PyC3A) to gadopentetate dimeglumine (Gd-DTPA) and to evaluate the excretion, pharmacokinetics

84 igate the effect of gadoxetic acid disodium (Gd-EOB-DTPA) on T2 relaxation times and apparent diffusi

85 ic Rare Earth Elements (AREE) for dissolved (Gd) and suspended (Ce and Nd) loads of river water.

86 or the three commonly used chelates Gd-DTPA, Gd-DTPA-BMA, and Gd-BT-DO3A, which were found to be 4.8

87 Mice underwent MPO-Gd- or DTPA-Gd-enhanced MR imaging on days 6, 8, and 10 after induct

88 irst relapse (9.0 vs 2.7, P = .03) than DTPA-Gd, which also correlated well with the presence and acc

89 n barrier (BBB) breakdown detected with DTPA-Gd enhancement.

90 ical inflammatory lesions compared with DTPA-Gd, including in cases in which there was no evidence of

91 R3 tumors from animals injected with DM-Dual Gd-ICG had increased fluorescence (p < 0.05, n = 6).

92 ced on MR two days after intravenous DM-Dual Gd-ICG injection compared to controls (SNR, CNR, p < 0.0

93 hether a dual-mode, dual-Gadolinium (DM-Dual-Gd-ICG) contrast agent can be used to visualize ovarian

94 stituting on Bi sites, were achieved for Dy, Gd, and Ho doping.

95 tions and rare-earth doping (Yb, Er, Ho, Dy, Gd, Sm, Nd, and La) on oxygen diffusion.

96 hedral metallofullerenes, formed by encaging Gd inside fullerenes like C80, can exhibit enhanced prot

97 parameters to the 4f states of encapsulated Gd atoms are discussed.

98 mbrane were hydrolyzed by PLA2, encapsulated Gd was released into bulk solution, resulting in a measu

99 The encapsulated Gd exhibited a low T1-weighted signal, due to low membra

100 -range interactions between the encapsulated Gd(III) and the protons of the H2O molecules outside the

101 ants with no change in gadolinium-enhancing [Gd+] lesion number with opicinumab vs 27 [79%] of 34 wit

102 The merits of gadolinium-based ESMA (Gd-ESMA) were compared with gadopentetic acid (Gd-DTPA)

103 methyl)benzene, Ln = La, Ce, Pr, Nd, Sm, Eu, Gd) have been synthesized and characterized.

104 trations of 10 REEs (La, Ce, Pr, Nd, Sm, Eu, Gd, Dy, Er, Yb) in ppb levels.

105 and minor metals (Y, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu) detected in sludges show

106 d)][Cp'3Ln] (Ln = Y, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm; Cp' = C5H4SiMe3) and the analogo

107 of lanthanide salts (La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Y) catalyzes oxidative C-O coupling

108 in the E4 loop near the TRPC5 extracellular Gd(3+) binding site, is critical for conferring the sens

109 tion, we observe a peculiar dependence of Fe/Gd magnetic coupling on the Mn spacer thickness.

110 ging (r, 0.83 for nanoparticles vs. 0.71 for Gd-imaging, P < 0.001).

111 ts (e.g., 24% for Zn, 50% for P, and 83% for Gd), indicating large anthropogenic inputs via the waste

112 copy shows the characteristic Dirac cone for Gd and Ho doping.

113 The transfer coefficient Ktrans for Gd-DTPA and the drug concentrations showed a good linear

114 +) and a 10(11)-fold greater selectivity for Gd(3+) over Zn(2+) compared with existing contrast agent

115 t (ProCA32) that exhibits high stability for Gd(3+) and a 10(11)-fold greater selectivity for Gd(3+)

116 Higher CNR values for Gd-ESMA further correlated with improved ejection fracti

117 modeling was used to design a series of four Gd complexes capable of forming an intramolecular H-bond

118 he cell with the 3D textile anode framework, Gd:CeO2 -Li/Na2 CO3 composite electrolyte, and Sm0.5 Sr0

119 t; the phosphate is completely released from Gd-TREN-MAM below pH 2.

120 ue is critical for establishing a functional Gd(3+) binding site, the Tyr-541 residue participates in

121 lements (Ag, As, Ce, Co, Cs, Cu, Eu, Fe, Ga, Gd, La, Lu, Mn, Mo, Nb, Nd, Ni, Pr, Rb, Sm, Te, Ti, Tl,

122 paramagnetic relaxation agent, gadodiamide (Gd(DTPA-BMA)).

123 s limit the use of iodinated and gadolinium (Gd)-based CT and MRI contrast media in renally compromis

124 fically, the clinically approved gadolinium (Gd)-based MR contrast agent, gadoteridol, was encapsulat

125 selective cation channel blocker Gadolinium (Gd(3+)).

126 inical disease than conventional gadolinium (Gd) imaging (r, 0.83 for nanoparticles vs. 0.71 for Gd-i

127 cental permeability of liposomal Gadolinium (Gd) nanoparticle contrast agents was evaluated in a preg

128 However, most gadolinium (Gd)-chelator MR contrast agents are limited by their rel

129 Although numerous gadolinium (Gd) containing metallofullerenes as diagnostic magnetic

130 both the spatial distribution of gadolinium (Gd) and other rare earth elements (REE) in surface water

131 MR) contrast agent with a single gadolinium (Gd) chelate using a quantitative MRI T1 mapping techniqu

132 d tomography (CT) enabled by the gadolinium (Gd) element contained in the UCNP.

133 ble condition recently linked to gadolinium (Gd) exposure during MRI with contrast.

134 CP-MS showed the presence of the intact GBCA Gd-HP-DO3A eight years after the administration to the p

135 ing IgA1 with galactose-deficient O-glycans (Gd-IgA1).

136 Finally, greater Gd-enhanced lesion length at baseline and greater optic

137 The highest Gd anomalies were observed in the southern reach of SFB,

138 for Ln = Ce(III), Nd(III), Sm(III), Eu(III), Gd(III); x = 2 for Ln = Ce(IV)) anions has been investig

139 into Xenopus laevis oocytes, and the Gd(III)-Gd(III) distances were determined by double electron-ele

140 umor enhancement and a sustained increase in Gd concentration in both heterotopic and orthotopic tumo

141 ncreased the signal intensity from tumors in Gd-DTPA-enhanced MRI.

142 biliary system and thus a decision to inject Gd-EOB-DTPA was taken.

143 ristic encapsulation of the lanthanide ions (Gd(3+)), preventing their release into the bioenvironmen

144 tion, and first-pass perfusion (0.03 mmol/kg Gd-DTPA bolus) at stress and rest (4-6 minutes IV adenos

145 d a 4f(n)5d(1) configuration for Ln = Y, La, Gd, Tb, Dy, Ho, Er.

146 emonstrate that the Gd(III) based spin label Gd-PyMTA is suitable for in-cell EPR.

147 glumine), and a novel experimental liposomal Gd agent.

148 both maternal and fetal safety of liposomal Gd is suggested.

149 w transplacental permeation of the liposomal Gd agent, while the clinical agent (Multihance) avidly p

150 dianion) and K2(THF)4[Ln(III)2(COT)4] (Ln = Gd (2), Er (3); THF = tetrahydrofuran, COT = cyclooctate

151 olated [Ln(Cp(ttt))2](+) cations (1-Ln; Ln = Gd, Ho, Er, Tm, Yb, Lu), synthesized by halide abstracti

152 bstraction of [Ln(Cp(ttt))2(Cl)] (2-Ln; Ln = Gd, Ho, Er, Tm, Yb, Lu).

153 rmal synthesis of the novel Na[LnSiO4] (Ln = Gd, Eu, Tb) disordered orthorhombic system is reported.

154 eterometallic wheel complexes {Cr8 Ln8 } (Ln=Gd, Dy and Y) with alternating metal centres are present

155 3 -HAN) (Cp*=pentamethylcyclopentadienyl; Ln=Gd, Tb, Dy; HAN=hexaazatrinaphthylene) proceeds through

156 in vitro experiments that metallofullerenol Gd@C82(OH)22 can effectively inhibit MMP-2 and MMP-9 wit

157 f-assembled patterns of Gd nano-fibers in Mg-Gd alloys for the purpose of improving their strength an

158 s on two trilayer systems Fe/Sc/Gd and Fe/Mn/Gd.

159 d for six different elements (C, Al, Cu, Mo, Gd, and W) using 40 fs, 800 nm Ti: Sapphire laser.

160 MRE to quantify (kPa) the elasticity modulus Gd and viscosity modulus Gl of three intracranially impl

161 MPO-Gd also helped detect more lesions during subclinical di

162 MPO-Gd helps detect earlier (5.2 vs 2.3 days before symptom

163 MPO-Gd specifically reveals lesions with inflammatory monocy

164 s 1.02 [95% CI: 0.89, 1.14]; P = .03) at MPO-Gd MR imaging.

165 Conclusion MPO-Gd showed elevated MPO activity in NAFLD mouse models an

166 The number of MPO-Gd-enhancing lesions correlated with early infiltration

167 with MPO-Gd, which proves specificity of MPO-Gd.

168 provides good preclinical evidence that MPO-Gd, a gadolinium-based magnetic resonance (MR) imaging p

169 Mice underwent MPO-Gd- or DTPA-Gd-enhanced MR imaging on days 6, 8, and 10

170 ven human liver biopsy samples underwent MPO-Gd-enhanced MR imaging ex vivo and subsequent histologic

171 Purpose To test whether MPO-Gd, an activatable molecular magnetic resonance (MR) ima

172 umine and in MPO knockout NASH mice with MPO-Gd, which proves specificity of MPO-Gd.

173 ental NASH and underwent MR imaging with MPO-Gd.

174 ]) than in control subjects (mean, -1.06 mug Gd/g bone mineral +/- 0.71) (P = .01).

175 y higher in exposed subjects (mean, 1.19 mug Gd/g bone mineral +/- 0.73 [standard deviation]) than in

176 concentration in bone increased by 0.39 mug Gd/g bone mineral +/- 0.14 per 1 mL of GBCA administered

177 clinical MRI contrast agents (CAs), namely, Gd-related adverse effect and decreasing sensitivity at

178 nce that, the metallofullerenol nanomaterial Gd@C82(OH)22, while essentially not toxic to normal mamm

179 core and outer Au layer of the nanoparticle (Gd-NM).

180 group and 0.85 for the opicinumab group] new Gd+ lesions per participant in both groups).

181 1-nm Gd nano-fibers, with a <c>-rod shape, are formed and hex

182 -up after aHSCT, no relapses occurred and no Gd enhancing lesions or new T2 lesions were seen on 314

183 een days 7 and 21 (1.8+/- versus 3.8; P=ns), Gd-ESMA showed markedly higher CNR on day 21 after MI (1

184 The accuracy of Gd-EOB-DTPA-3T-MR significantly improves for lesions <20

185 e TRPC5R593A mutant, whereas the addition of Gd(3+) rescues the mutant's sensitivity to GPCR-Gq/11-PL

186 different before and after administration of Gd-EOB-DTPA.

187 fore and after intravenous administration of Gd-EOB-DTPA.

188 niquely determines the initial adsorption of Gd@C82(OH)22 on MMP-2, and then its further location of

189 -ESMA resulted in significantly lower CNR of Gd-ESMA at the infarct site (P=0.0019).

190 er population depended on cosequestration of Gd(3+) and (225)Ac(3+) ions.

191 vior were observed in the single crystals of Gd(30)Ru(4.92)Sn(30.54) and Tb(30)Ru(6)Sn(29.5).

192 measurements at the N4,5 absorption edges of Gd to validate the high degree of circularity, brightnes

193 cement MRI revealed prolonged enhancement of Gd-ESMA in the postischemic scar compared with Gd-DTPA.

194 Furthermore, MRI-based estimates of Gd-DTPA transport across these barriers might be useful

195 ronic structure and spin flip excitations of Gd 4f electrons.

196 These ZES-SPIONs are free of Gd and show a high T1 contrast power.

197 Measurements of Gd-NM revealed a strongly enhanced T1 relaxivity (r1 app

198 illustrated how the inhibitory mechanism of Gd@C82(OH)22 is distinguished between the two gelatinase

199 urements of RE = Gd show that the moments of Gd ferromagnetically order with the moments of [MnSb4](9

200 Here, we report self-assembled patterns of Gd nano-fibers in Mg-Gd alloys for the purpose of improv

201 equester (225)Ac(3+) ions in the presence of Gd(3+) ions and retain them after a human serum challeng

202 p)) experienced by nuclei in the presence of Gd(3+), so that R(2p) represents a reliable predictive t

203 Presence of Gd(III) furthermore amplifies the effect likely by accel

204 The imaging properties of Gd-ESMA allow quantification of intrascar elastin conten

205 rotational motion and increase relaxivity of Gd complexes.

206 14.06 mM(-1) s(-1) ), low risk of release of Gd ions, and NIR-triggered drug release.

207 However, the underlying key energy scales of Gd x Sc3-x N@C80 (x = 1-3) remain unclear.

208 Here the electronic states of Gd atom trapped in open Fe corrals on Ag(111) were studi

209 display T1 relaxivity comparable to that of Gd(III)-based contrast agents and undergo spontaneous cy

210 tumour microenvironment, cellular uptake of Gd@C82(OH)22 is facilitated where it functions as a bi-p

211 ris(carbonyl))tris(4-ox o-4H-pyran-3-olate) (Gd-TREN-MAM).

212 rain parenchyma, enabling their detection on Gd and Gl parametric maps.

213 astic x-ray scattering (RIXS) experiments on Gd x Sc3-x N@C80 at Gd N 4,5-edges to directly study the

214 n at the Ce site in CeRhIn5, either by Nd or Gd, induces a zero-field magnetic instability inside the

215 ere clinical relapse, appearance of a new or Gd-enhancing lesion on MRI, and sustained progression of

216 us muscle at 9 seconds following Mn-PyC3A or Gd-DTPA injection.

217 r x values of RE = Nd but not for RE = Sm or Gd at any value of x.

218 ed proton relaxitivities compared with other Gd-chelates, making them the promising contrast agents f

219 nterparts around the FeMo-cofactor, oxidized Gd-MoFeP features an unusual Tyr coordination to its P-c

220 EPR analysis of the oxidized Gd-MoFeP P-cluster confirmed that it is a 2-e(-) oxidize

221 e spin labeled peptide H-AP10C(Gd-PyMTA)P10C(Gd-PyMTA)P10-NH2 is inserted into cell membranes, coinci

222 The resulting peptide, H-AP10C(Gd-PyMTA)P10C(Gd-PyMTA)P10-NH2, as well as the model compound Gd-space

223 and gadolinium diethylenetriamine-pentaacid (Gd-DTPA).

224 ed significantly greater accumulation of PGC-Gd-DTPA-F in the graft area after immune attack initiate

225 In water at neutral pH, Gd-TREN-MAM binds phosphate with high affinity (Ka = 1.3

226 REE content, in particular Sm, Th, La, Pr, Gd, and especially Ce and Nd varied between species.

227 recently discovered Ln(2+) ions of Ln = Pr, Gd, Tb, Ho, Y, Er, and Lu in 2.

228 substitutionally replaced by a RE atom (RE = Gd, Dy, and Ho), is a predicted QAHE system.

229 contrast, the magnetic measurements of RE = Gd show that the moments of Gd ferromagnetically order w

230 re reported, abbreviated as {Ni64 RE96 } (RE=Gd, Dy, and Y) and obtained by a mixed-ligand approach,

231 E1/RE2 mixtures, where RE1 = La-Sm and RE2 = Gd-Lu, with emphasis on Eu/Y separations for potential a

232 While reduced Gd-MoFeP is structurally identical to previously charact

233 ely low relaxivity and high risk of released-Gd-ions-associated toxicity.

234 based on the use of: (i) reduction resistant Gd(3+) chelates as spin labels, (ii) high frequency (94.

235 The Eu(II) ion rivals Gd(III) in its ability to enhance contrast in magnetic r

236 mental results on two trilayer systems Fe/Sc/Gd and Fe/Mn/Gd.

237 Ablation after TSL injection showed [Gd(HPDO3A)(H2O)] and dox release along the tumor rim, mi

238 fluorescein and "eat-me" phagocytic signals (Gd-FITC-LiLa) a) demonstrates high relaxivity that impro

239 molecular contrast agent containing a single Gd ion showed significant tumor enhancement and a sustai

240 This single Gd-containing PTPmu agent was more effective than our pr

241 e oligoPPEs as spacers for the water-soluble Gd rulers of the type Gd-PyMTA-spacer-Gd-PyMTA with Gd-G

242 NH2, as well as the model compound Gd-spacer-Gd, which consists of a spacer of well-known stiffness,

243 oluble Gd rulers of the type Gd-PyMTA-spacer-Gd-PyMTA with Gd-Gd distances of 2.1-10.9 nm.

244 l (l solution)(-1)) bath solution stimulated Gd(3+)-sensitive ICat in smooth muscle cells that were r

245 Such Gd-fiber patterns are able to regulate the relative acti

246 ive number of new T1 gadolinium-enhanced (T1 Gd+) lesions per patient recorded every 4 weeks from wee

247 g significantly reduced the number of new T1 Gd+ lesions and showed a beneficial effect on clinical e

248 The mean cumulative number of new T1 Gd+ lesions at weeks 12-24 was significantly lower in th

249 /TE 455/9, 7 ms, T2 (TR/TE 5300/67 ms), T1 + Gd-DTPA (contrast agent Gd-DTPA at 0.2 mmol/kg).

250 or more than 1 h, about 10 times longer than Gd-based CAs currently used in clinic.

251 20-fold more resistant to dissociation than [Gd(DTPA)(H2O)](2-).

252 rthermore, our in silico study revealed that Gd@C82(OH)22 could indirectly inhibit the proteolysis of

253 The Gd content of excised placentae and fetuses was measured

254 The Gd(III) complex of DO3A-N-alpha-aminopropionate, Gd(DOTA

255 The Gd-EOB-DTPA in combination with regular T2-weighted MRCP

256 njected into Xenopus laevis oocytes, and the Gd(III)-Gd(III) distances were determined by double elec

257 Because the Gd(III) ion remains complexed by its ligand, even under

258 tional flexibility of the tether between the Gd(III) ion and the Calpha of the cysteine moiety into a

259 Exchanging the Gd(3+) ion for the radionuclide, (111)In, also allowed d

260 urements revealed a temporal increase in the Gd anomaly in SFB from the early 1990s to the present.

261 es in the Co oxidation state, but not in the Gd, suggesting that the GdOx transmits oxygen but does n

262 phase successfully avoids segregation of the Gd dopant and depletion of oxygen vacancies at the Ce0.8

263 Here, we demonstrate that the Gd(III) based spin label Gd-PyMTA is suitable for in-cel

264 al components in mixtures according to their Gd(3+)-complexing ability.

265 ic NIR-MR contrast agents that contain three Gd(III) chelates and an IR-783 dye moiety.

266 h relative yield, and encapsulation of three Gd(3+) ions per molecule as illustrated by the previousl

267 eted contrast agents containing one to three Gd(III) chelates per molecule.

268 nd of gadolinium metallofullerene with three Gd ions in one carbon cage, acts as a satellite anchorin

269 fective than our previous version with three Gd ions.

270 Thus, Gd-metallofullerenol is identified as a kind of non-toxi

271 onsisting of anti-glycan antibodies bound to Gd-IgA1.

272 hich was varied across the series from Ce to Gd, and (2) the Ln oxidation state (when practical, i.e.

273 y excretion with similar pharmacokinetics to Gd-DTPA (area under the curve between 0 and 30 minutes,

274 64.3% sequence identity, their responses to Gd@C82(OH)22 were quite different.

275 nce imaging (MRI) contrast agent, CREKA-Tris(Gd-DOTA)3 (Gd-DOTA (4,7,10-tris(carboxymethyl)-1,4,7,10-

276 monstrate that molecular MRI with CREKA-Tris(Gd-DOTA)3 may facilitate early detection of high-risk br

277 We find that CREKA-Tris(Gd-DOTA)3 provides robust contrast enhancement in the me

278 Here we assess the capability of CREKA-Tris(Gd-DOTA)3 to detect micrometastasis with MRI in co-regis

279 or before ablation ensured homogeneous TSL, [Gd(HPDO3A)(H2O)], and dox delivery across the tumor.

280 Tyr-541 residue participates in fine-tuning Gd(3+)-sensitivity, and that the Asn-584 residue determi

281 for the water-soluble Gd rulers of the type Gd-PyMTA-spacer-Gd-PyMTA with Gd-Gd distances of 2.1-10.

282 eral hospitals and research centers that use Gd-based contrast agents for magnetic resonance imaging.

283 chemia, we observed pericytes (at d 2, using Gd-nestin, by eyedrop solution), significant photorecept

284 ar paramagnetic relaxation enhancement using Gd(3+)-tagged vesicles, to a predominantly positively ch

285 hree new high-affinity, low-molecular-weight Gd(III) -based PSMA-targeted contrast agents containing

286 EST- (Tb(3+), Yb(3+)), or (iii) T1-weighted (Gd(3+)) MRI.

287 ii) optic nerve post-gadolinium T1-weighted (Gd-enhanced lesion length); and (iv) brain diffusion-wei

288 e-silica layer-Au shell nanoparticles, where Gd(III) ions are encapsulated within the silica layer be

289 sing the emerging challenges associated with Gd-based clinical MRI contrast agents (CAs), namely, Gd-

290 nd hexagonally patterned in association with Gd segregations along dislocations that nucleated during

291 -ESMA in the postischemic scar compared with Gd-DTPA.

292 Following complexation with Gd, this PTPmu-targeted molecular contrast agent contain

293 At the same time, the CE-MRI of kidney with Gd-DOTA showed significantly improved signal enhancement

294 10-NH2 was site-directedly spin labeled with Gd-PyMTA at both cysteine moieties.

295 rs of the type Gd-PyMTA-spacer-Gd-PyMTA with Gd-Gd distances of 2.1-10.9 nm.

296 of highly sensitive contrast agents without Gd(3+) toxicity.

297 In ferromagnetic Eu(1-x)Gd(x)O, we thereby demonstrate the strengthening as well

298 nse of titanate pyrochlores (A2Ti2O7, A = Y, Gd and Sm) to electronic excitation is investigated util

299 oselective bisaddition of M3N@Ih-C80 (M = Y, Gd) was observed for the first time in the Prato reactio

300 metallofullerenes M2C2@C1(51383)-C84 (M = Y, Gd).